ReviewFolia microbiologica2026
A comprehensive review on antifungal compounds and biogenic nanoparticles from marine actinobacteria against opportunistic fungal infections.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative volatilomics identifies ubiquitous sulfur compounds inhibiting the fungal pathogenMicrobiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wide spread of opportunistic fungal infections among several immunocompromised patients has become a major health concern. A surge in the prevalence of multi drug resistant pathogenic fungi mainly Candida and Aspergillus sp. to current antifungals has lead scientists to search for new lead compounds which can address the issues of emerging fungal infections. Majority of the antifungals used currently are less effective against these pathogens and scenario of developing resistance to azoles is also a major concern. The marine environment has become a greatest treasure house for a large number of bioactive compounds due to its extreme habitat. Several bioactive compounds have been extracted and characterized from marine sources. Nevertheless, identification of antifungal compounds from marine sources especially from marine actinobacteria is less investigated so far. The existing antifungal compounds have several limitations like toxicity, poor biocompatibility and low efficacy. Hence, the development of novel antifungal compounds from marine actinobacteria with greater potency can be an attractive solution to fight this hurdle of fungal infections. From active investigation and studies reported so far, antifungal compounds from marine actinobacteria have been addressed in this review. In addition to that, this review also focuses on actinobacteria mediated nanoparticles in the treatment of opportunistic fungal infections. Nanoparticles can be a promising approach in antifungal therapy due to their nanoscale size and surface properties which enhances treatment efficacy through disruption of fungal cell membranes. Therefore, marine antifungal compounds along with the application of nanotechnology hope to contribute better solutions to opportunistic fungal infections.
Indexed as
Identifiers
41082034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.